Development of an automated manufacturing process for large-scale production of autologous T cell therapies

Engineered T cell therapies have shown significant clinical success. However, current manufacturing capabilities present a challenge in bringing these therapies to patients. Furthermore, the cost of development and manufacturing is still extremely high due to complexity of the manufacturing process....

Descripción completa

Detalles Bibliográficos
Autores principales: Francis, Natalie, Braun, Marion, Neagle, Sarah, Peiffer, Sabine, Bohn, Alexander, Rosenthal, Alexander, Olbrich, Tanita, Lollies, Sophia, Ilsmann, Keijo, Hauck, Carola, Gerstmayer, Bernhard, Weber, Silvio, Kirkpatrick, Aileen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10544074/
https://www.ncbi.nlm.nih.gov/pubmed/37790245
http://dx.doi.org/10.1016/j.omtm.2023.101114

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10544074/
https://www.ncbi.nlm.nih.gov/pubmed/37790245
http://dx.doi.org/10.1016/j.omtm.2023.101114

Ejemplares similares